IBDEI37D ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,53804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53804,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-neg, nodes mult site
 ;;^UTILITY(U,$J,358.3,53804,1,4,0)
 ;;=4^C84.78
 ;;^UTILITY(U,$J,358.3,53804,2)
 ;;=^5001669
 ;;^UTILITY(U,$J,358.3,53805,0)
 ;;=C81.08^^253^2724^43
 ;;^UTILITY(U,$J,358.3,53805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53805,1,3,0)
 ;;=3^Nodular lymphocyte predom Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,53805,1,4,0)
 ;;=4^C81.08
 ;;^UTILITY(U,$J,358.3,53805,2)
 ;;=^5001399
 ;;^UTILITY(U,$J,358.3,53806,0)
 ;;=C81.48^^253^2724^28
 ;;^UTILITY(U,$J,358.3,53806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53806,1,3,0)
 ;;=3^Lymp-rich classical Hodgkin lymphoma, lymph nodes mult site
 ;;^UTILITY(U,$J,358.3,53806,1,4,0)
 ;;=4^C81.48
 ;;^UTILITY(U,$J,358.3,53806,2)
 ;;=^5001439
 ;;^UTILITY(U,$J,358.3,53807,0)
 ;;=C81.18^^253^2724^44
 ;;^UTILITY(U,$J,358.3,53807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53807,1,3,0)
 ;;=3^Nodular sclerosis class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,53807,1,4,0)
 ;;=4^C81.18
 ;;^UTILITY(U,$J,358.3,53807,2)
 ;;=^5001409
 ;;^UTILITY(U,$J,358.3,53808,0)
 ;;=C81.28^^253^2724^36
 ;;^UTILITY(U,$J,358.3,53808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53808,1,3,0)
 ;;=3^Mixed cellular classical Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,53808,1,4,0)
 ;;=4^C81.28
 ;;^UTILITY(U,$J,358.3,53808,2)
 ;;=^5001419
 ;;^UTILITY(U,$J,358.3,53809,0)
 ;;=C81.38^^253^2724^30
 ;;^UTILITY(U,$J,358.3,53809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53809,1,3,0)
 ;;=3^Lymphocy depleted class Hodgkin lymphoma, nodes mult site
 ;;^UTILITY(U,$J,358.3,53809,1,4,0)
 ;;=4^C81.38
 ;;^UTILITY(U,$J,358.3,53809,2)
 ;;=^5001429
 ;;^UTILITY(U,$J,358.3,53810,0)
 ;;=C82.98^^253^2724^26
 ;;^UTILITY(U,$J,358.3,53810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53810,1,3,0)
 ;;=3^Follicular lymphoma, unsp, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,53810,1,4,0)
 ;;=4^C82.98
 ;;^UTILITY(U,$J,358.3,53810,2)
 ;;=^5001549
 ;;^UTILITY(U,$J,358.3,53811,0)
 ;;=C84.08^^253^2724^42
 ;;^UTILITY(U,$J,358.3,53811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53811,1,3,0)
 ;;=3^Mycosis fungoides, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,53811,1,4,0)
 ;;=4^C84.08
 ;;^UTILITY(U,$J,358.3,53811,2)
 ;;=^5001629
 ;;^UTILITY(U,$J,358.3,53812,0)
 ;;=C84.18^^253^2724^48
 ;;^UTILITY(U,$J,358.3,53812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53812,1,3,0)
 ;;=3^Sezary disease, lymph nodes of multiple sites
 ;;^UTILITY(U,$J,358.3,53812,1,4,0)
 ;;=4^C84.18
 ;;^UTILITY(U,$J,358.3,53812,2)
 ;;=^5001639
 ;;^UTILITY(U,$J,358.3,53813,0)
 ;;=C91.40^^253^2724^27
 ;;^UTILITY(U,$J,358.3,53813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53813,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,53813,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,53813,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,53814,0)
 ;;=C96.0^^253^2724^39
 ;;^UTILITY(U,$J,358.3,53814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53814,1,3,0)
 ;;=3^Multifocal and multisystemic Langerhans-cell histiocytosis
 ;;^UTILITY(U,$J,358.3,53814,1,4,0)
 ;;=4^C96.0
 ;;^UTILITY(U,$J,358.3,53814,2)
 ;;=^5001859
 ;;^UTILITY(U,$J,358.3,53815,0)
 ;;=C96.2^^253^2724^34
 ;;^UTILITY(U,$J,358.3,53815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,53815,1,3,0)
 ;;=3^Malignant mast cell tumor
 ;;^UTILITY(U,$J,358.3,53815,1,4,0)
 ;;=4^C96.2
 ;;^UTILITY(U,$J,358.3,53815,2)
 ;;=^5001860
 ;;^UTILITY(U,$J,358.3,53816,0)
 ;;=C84.48^^253^2724^45
